First-in-Human Study of an Oral Formulation of the GLP-1/GIP Co-Agonist VK2735 in Healthy Adults

被引：0
|
作者：
Neutel, Joel
Rowland, Angela
Bell, Francesca
Rooney, Carmela
Rask, Chris
Steele, Becky
Ji, Summer
Barker, Geoff
Mancini, Marianne
Lian, Brian
机构：
来源：
OBESITY | 2024年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Poster-017
引用
收藏
页码：61 / 62
页数：2
相关论文
共 50 条
  • [1] First-in-Human Single and Multiple Dose Study of the Dual GLP-1/GIP Agonist VK2735 in Healthy Adults
    Lian, Brian
    Mancini, Marianne
    Ji, Summer
    Barker, Geoff
    Neutel, Joel
    Rowland, Angela
    Bell, Francesca
    Rooney, Carmela
    Steele, Becky
    OBESITY, 2023, 31 : 41 - 42
  • [2] Results From the 13-Week VENTURE Phase 2a Study of the GLP-1/GIP Co-Agonist VK2735 in Obese Subjects
    Neutel, Joel
    Alkhouri, Naim
    Bays, Harold
    Bollepalli, Sureka
    Bowman, Kelly
    Hedges, Parke
    Pullman, John
    Reiss, Gary
    Ji, Summer
    Barker, Geoff
    Stubbe, Scott
    Mancini, Marianne
    Lian, Brian
    OBESITY, 2024, 32 : 62 - 62
  • [3] Novel GIP/GLP-1/Glucagon Receptor Agonist LY3437943: A First-in-Human Dose Study in Healthy Subjects
    Urva, Shweta
    Du, Yu
    Thomas, Melissa K.
    Milicevic, Zvonko
    Coskun, Tamer
    Benson, Charles
    Loghin, Corina
    DIABETES, 2021, 70
  • [4] Novel GIP/GLP-1/glucagon receptor agonist LY3437943: a first in human dose study in healthy subjects
    Benson, C. T.
    Loghin, C.
    Du, Y.
    Thomas, M. K.
    Coskun, T.
    Urva, S.
    Milicevic, Z.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 116 - 116
  • [5] Identification of a Multi-Component Formulation for Intestinal Delivery of a GLP-1/Glucagon Co-agonist Peptide
    Huyen Tran
    Patel, Phenil J.
    Aburub, Aktham
    Sperry, Andrea
    Estwick, Selina
    ElSayed, Mohamed E. H.
    Datta-Mannan, Amita
    PHARMACEUTICAL RESEARCH, 2022, 39 (10) : 2555 - 2567
  • [6] Identification of a Multi-Component Formulation for Intestinal Delivery of a GLP-1/Glucagon Co-agonist Peptide
    Huyen Tran
    Phenil J. Patel
    Aktham Aburub
    Andrea Sperry
    Selina Estwick
    Mohamed E. H. ElSayed
    Amita Datta –Mannan
    Pharmaceutical Research, 2022, 39 : 2555 - 2567
  • [7] A First-in-Human Single Ascending Dose Study of GSBR-1290, a Novel Small Molecule GLP-1 Receptor Agonist, in Healthy Volunteers
    Coll, Blai
    Zhang, Jinqiang J.
    Jacober, Scott J.
    Argent, Christopher
    Ibarra, Lani
    Snyder, Margo
    Bach, Mark A.
    DIABETES, 2023, 72
  • [8] A First-in-Human Study of RGT-075, a Novel, Orally Bioavailable, Small-Molecule GLP-1 Receptor Agonist, in Healthy Adult Subjects
    Pirner, Mark A.
    Lin, Jing
    Liu, Feng
    Yao, Lili
    Zettler, Marjorie E.
    Valacer, David J.
    DIABETES, 2022, 71
  • [9] A First-in-Human Single- and Multiple-Ascending Dose Study Evaluating Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Oral Nonpeptide GLP-1 Receptor Agonist in Healthy Subjects
    Pratt, Edward J.
    Ma, Xiaosu
    Liu, Rong
    Robins, Deborah A.
    Sloop, Kyle
    Benson, Charles
    DIABETES, 2022, 71
  • [10] Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
    Michael A. Nauck
    David A. D‘Alessio
    Cardiovascular Diabetology, 21
12345